Central Nervous System Therapeutics Market Size, Share & Trends Analysis Report By Disease, By Drug Class (Anticonvulsants, CNS Stimulants), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

Market Size & Trends

The global central nervous system therapeutics market size was estimated at USD 140.44 million in 2024 and is projected to grow at a CAGR of 10.4% from 2025 to 2030. The World Health Organization (WHO) reports that the number of individuals aged 60 and older is projected to reach 2.1 billion by 2050. This demographic shift is contributing to an increased prevalence of CNS disorders, particularly neurodegenerative diseases such as Alzheimer’s and Parkinson’s. With older adults being more susceptible to these conditions, there is a burgeoning demand for effective therapeutic interventions, creating lucrative opportunities for stakeholders within the industry.

In addition to the aging population, recent estimates by the National Multiple Sclerosis Society indicate that approximately 2.9 million people are affected by multiple sclerosis globally, among which approximately 1 million are Americans. As these conditions continue to escalate in incidence, healthcare systems are compelled to seek advanced therapies to manage and treat affected individuals. This surge in demand necessitates innovative solutions, prompting pharmaceutical companies to prioritize the development of cutting-edge therapeutics.

Furthermore, the growing awareness surrounding mental health issues plays a pivotal role in shaping the CNS therapeutics landscape. As society becomes more open to discussing mental health conditions such as depression and anxiety, the demand for effective treatment options is on the rise. The increasing recognition of mental health challenges influences both consumer behavior and healthcare policies, further propelling the need for advanced CNS therapeutic interventions.

Ongoing research and development efforts underscore the dynamic nature of CNS treatment. Pharmaceutical companies are investing heavily in R&D, driven by technological advancements in neurology, molecular biology, and neuroimaging technologies. Innovations in personalized medicine and gene therapies are paving the way for novel treatment modalities, enhancing the potential for success in addressing a spectrum of CNS disorders.

Disease Insights

Mental health therapeutics led the market with a revenue share of 40.2% in 2024. The rising incidence of conditions such as anxiety, depression, and schizophrenia underscores the need for effective therapeutic solutions. Concurrently, the aging population exacerbates mental health challenges, prompting increased research and development efforts by pharmaceutical companies to enhance treatment availability and efficacy.

Neurodegenerative diseases are projected to witness the fastest growth with a CAGR of 11.5% over the forecast period, owing to the increasing prevalence of conditions such as Alzheimer’s, Parkinson’s, and multiple sclerosis. The aging population intensifies the need for advanced therapeutic options, while heightened investment in research and development accelerates the availability of innovative treatments to address these debilitating disorders.

Drug Class Insights

CNS stimulants held the largest revenue share of 25.5% in 2024 due to the increasing prevalence of disorders such as ADHD and narcolepsy. The introduction of newly approved stimulant medications expands treatment options, while heightened awareness of mental health and effective management of conditions such as obstructive sleep apnea further propels this demand.

Anticonvulsants are expected to register significant growth with a CAGR of 11.5% over the forecast period. With around 50 million individuals globally affected by epilepsy, there is a critical demand for effective treatment options. Advancements in drug development and heightened awareness of available therapies, coupled with patent expirations of key anticonvulsants, are enhancing accessibility through generics.

Distribution Channel Insights

Hospital pharmacies dominated the market and accounted for a share of 46.3% in 2024. Hospitals are crucial for delivering acute care and specialized treatments, particularly in dispensing CNS medications. The preference for hospital pharmacies stems from the need for immediate medication access, continuous patient management, and effective handling of complex cases. As CNS disorders become more prevalent, hospital pharmacies are well-positioned to meet the rising demand for effective therapeutic interventions.

Retail pharmacies are expected to witness the fastest growth of 12.1% over the forecast period. The transition to outpatient care and telemedicine has amplified the demand for accessible medication options. Patients favor retail pharmacies for prescription refills and routine CNS condition management. Moreover, the growth of community-based mental health services and decentralized healthcare models supports this trend, as retail pharmacies provide competitive pricing and discounts.

Regional Insights

North America central nervous system therapeutics market dominated the global market with a revenue share of 39.5% in 2024. North America faces a substantial prevalence of neurodegenerative disorders and mental health issues, supported by advanced healthcare infrastructure and significant government investments. The strong presence of leading pharmaceutical companies, coupled with heightened awareness of CNS disorders and active research initiatives, stimulates demand for innovative treatment solutions in the region.

U.S. Central Nervous System Therapeutics Market Trends

The central nervous system therapeutics market in U.S. dominated the North America market with a revenue share of 89.3% in 2024, owing to the high prevalence of neurological disorders such as Alzheimer’s and Parkinson’s diseases. A robust healthcare infrastructure and substantial investments in research and development foster innovative treatment options, while an aging population further drives the demand for effective CNS therapies.

Europe Central Nervous System Therapeutics Market Trends

Europe central nervous system therapeutics market held substantial market share in 2024. The region features a robust healthcare system that fosters advanced research and development, leading to the emergence of innovative therapies. Heightened public awareness campaigns and favorable regulatory frameworks contribute to market expansion.

The central nervous system therapeutics market in Germany is expected to grow in the forecast period. Germany has established multidisciplinary task forces to enhance treatment protocols for CNS disorders. The country benefits from a strong regulatory framework supporting drug development and access to advanced therapies. Furthermore, growing public awareness and increased funding for mental health initiatives boost demand for effective CNS treatments.

Asia Pacific Central Nervous System Therapeutics Market Trends

Asia Pacific central nervous system therapeutics market is expected to register the fastest CAGR of 11.1% in the forecast period. Market growth in the Asia-Pacific region is propelled by rising healthcare investments and a substantial patient population with unmet medical needs. Countries such as China and India are expanding their pharmaceutical markets, enhancing access to CNS treatments. Increased awareness of mental health issues and government initiatives further drive market demand.

The central nervous system therapeutics market in China held a substantial share of the Asia Pacific central nervous system therapeutics market in 2024, fueled by a rising incidence of neurological disorders, particularly Parkinson’s disease. The modernization of healthcare facilities and the expanded availability of innovative CNS treatments improve patient access to care. Furthermore, China’s emphasis on developing biologics and anti-Parkinson medications positions it as a key player in the global industry.

Key Central Nervous System Therapeutics Company Insights

Some key companies operating in the market include Biogen; Otsuka Pharmaceutical Co., Ltd.; Eli Lilly and Company; Merck & Co., Inc.; among others. Key strategies involve strong R&D, strategic partnerships with academic institutions, and awareness campaigns for CNS disorders. Companies prioritize regulatory approvals and collaboration to develop advanced therapies.

• Biogen is dedicated to advancing innovative therapies for neurological and neurodegenerative diseases, particularly multiple sclerosis, Alzheimer’s disease, and spinal muscular atrophy. Renowned for its flagship product Tecfidera, the company engages in research collaborations, including a partnership with Sangamo Therapeutics to enhance gene therapy for neurological conditions.

• Takeda specializes in diverse therapeutic areas, including neuroscience, and is committed to developing treatments for conditions such as ADHD and major depressive disorder. The company focuses on R&D to innovate CNS therapeutics, addressing unmet medical needs in mental health and neurodegenerative diseases.

Recent Developments

• In May 2024, AC Immune and Takeda entered an exclusive agreement for ACI-24.060, an Alzheimer’s immunotherapy, involving a USD 100 million upfront payment and potential milestones exceeding USD 2.1 billion.

• In March 2024, Ultomiris received FDA approval as the first long-acting C5 complement inhibitor for treating adults with anti-AQP4 antibody-positive NMOSD, demonstrating significant relapse reduction.

• In January 2024, Biogen realigned its resources, prioritizing LEQEMBI over ADUHELM, focusing on advancing innovative Alzheimer’s treatments, and halting the development of ADUHELM without safety or efficacy concerns.

Central Nervous System Therapeutics Market Report Scope

Global Central Nervous System Therapeutics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global central nervous system therapeutics market report based on disease, drug class, distribution channel, and region:

• Disease Outlook (Revenue, USD Million, 2018 - 2030)

  • Neurovascular Diseases

  • CNS Trauma

  • Mental Health

    • Anxiety Disorders

    • Epilepsy

    • Mood Disorders

    • Psychotic Disorders

    • Others

  • Neurodegenerative Diseases

    • Alzheimer’s Disease

    • Parkinsosn’s Disease

    • Multiple Sclerosis

    • Huntington’s Disease

    • Amytrophic Lateral Sclerosis

    • Others

  • Infectious Diseases

  • CNS Cancer

  • Others

• Drug Class Outlook (Revenue, USD Million, 2018 - 2030)

  • Anesthetics

  • Anticonvulsants

  • Antiemetics

  • CNS Stimulants

  • Pain Relievers

  • Others

• Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospital Pharmacies

  • Retail Pharmacies

  • Others

• Regional Outlook (Revenue, USD Billion, 2018 - 2030)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait